481
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective

, &
Pages 907-916 | Accepted 25 Apr 2013, Published online: 23 May 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Daniel Resende Faleiros, Juliana Álvares, Alessandra Maciel Almeida, Vânia Eloisa de Araújo, Eli Iola Gurgel Andrade, Brian B. Godman, Francisco A. Acurcio & Augusto A. Guerra Júnior. (2016) Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 257-266.
Read now

Articles from other publishers (2)

Parth Shah, Charles J. Glueck, Vybhav Jetty, Naila Goldenberg, Matan Rothschild, Rashid Riaz, Gregory Duhon & Ping Wang. (2016) Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center. Lipids in Health and Disease 15:1.
Crossref
Josephine Mauskopf & Stephanie Earnshaw. (2016) A Methodological Review of US Budget-Impact Models for New Drugs. PharmacoEconomics 34:11, pages 1111-1131.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.